Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been assigned an average recommendation of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $30.20.

A number of equities analysts recently issued reports on GLUE shares. Wells Fargo & Company upped their price target on Monte Rosa Therapeutics from $22.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday. Jefferies Financial Group reaffirmed a “buy” rating and issued a $31.00 target price on shares of Monte Rosa Therapeutics in a research report on Wednesday. Zacks Research upgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 6th. Guggenheim upped their price objective on shares of Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Wedbush reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Monte Rosa Therapeutics in a report on Wednesday.

Trending Headlines about Monte Rosa Therapeutics

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Interim Phase I data showed MRT‑8102 produces deep NEK7 degradation and drove a large reduction in inflammation markers, which triggered a big intraday rally in the stock. GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
• Positive Sentiment: Early trial readouts reported ~85% CRP reduction (a key inflammation marker), reinforcing clinical promise for MRT‑8102 and sparking investor enthusiasm. Monte Rosa stock surges after positive data shows 85% CRP reduction
• Positive Sentiment: Analysts reacted to the clinical news with bullish moves — Guggenheim raised its PT to $34 and issued a Buy, and Wells Fargo raised its PT to $30 with an Overweight. These actions support upside from fundamentals if clinical progress continues. Benzinga
• Positive Sentiment: Zacks upgraded GLUE from Hold to Strong Buy amid the data-driven momentum, adding to short‑term buyer interest. Zacks.com upgrade
• Neutral Sentiment: Several market watchers flagged GLUE as a “stock on the move,” highlighting momentum and technical strength that could attract momentum traders. Monte Rosa Therapeutics (GLUE) is on the Move
• Negative Sentiment: Monte Rosa priced an underwritten public offering to raise roughly $300 million: 11,125,000 shares at $24.00 plus 1,375,000 pre‑funded warrants at $23.9999. The timing — immediately after a sharp rally — increases share supply and dilution risk, which likely weighed on the stock. Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

Monte Rosa Therapeutics Price Performance

NASDAQ:GLUE opened at $24.28 on Friday. Monte Rosa Therapeutics has a 12 month low of $3.50 and a 12 month high of $25.77. The firm has a market capitalization of $1.58 billion, a PE ratio of 75.88 and a beta of 1.60. The business’s fifty day moving average price is $16.01 and its 200 day moving average price is $9.78.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.06. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%.The business had revenue of $12.77 million during the quarter, compared to analysts’ expectations of $7.37 million. As a group, equities analysts anticipate that Monte Rosa Therapeutics will post -1.49 EPS for the current year.

Insider Buying and Selling

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $23.49, for a total transaction of $128,396.34. Following the transaction, the chief executive officer owned 618,937 shares of the company’s stock, valued at $14,538,830.13. The trade was a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 6.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Hedge funds have recently modified their holdings of the business. Royce & Associates LP raised its position in Monte Rosa Therapeutics by 8.3% in the 3rd quarter. Royce & Associates LP now owns 11,024 shares of the company’s stock valued at $82,000 after purchasing an additional 848 shares during the last quarter. GAMMA Investing LLC purchased a new stake in shares of Monte Rosa Therapeutics in the fourth quarter valued at about $30,000. The Manufacturers Life Insurance Company boosted its stake in shares of Monte Rosa Therapeutics by 2.2% during the second quarter. The Manufacturers Life Insurance Company now owns 119,836 shares of the company’s stock worth $540,000 after buying an additional 2,529 shares during the period. Lazard Asset Management LLC grew its holdings in shares of Monte Rosa Therapeutics by 42.9% during the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after buying an additional 3,262 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in Monte Rosa Therapeutics by 20.2% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,289 shares of the company’s stock valued at $357,000 after acquiring an additional 3,746 shares during the period. 79.96% of the stock is currently owned by hedge funds and other institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.